Visa isn’t the biggest sweet in Berkshire’s jar, not by a long shot (a mere 0.9% of the total), but it’s a reliable one. Old Buffett was always going on about ‘moats’ – not the watery kind, mind you, but things that keep the competitors at bay. Visa’s moat is its reach. It’s everywhere!
But does this represent a genuine opportunity for the discerning investor, or merely another gilded cage constructed to ensnare the unwary? The question demands a sober assessment, a peeling back of the layers of hype and illusion.
This AbbVie thing. They’re a “Dividend King.” A king. Seriously? Like they’re royalty because they’ve been handing out a little extra change for fifty years? It’s just… aggressive. But, okay, they’ve been doing it. Fifty years. It’s impressive, I suppose. It means they haven’t completely messed things up for half a century. That’s… a low bar, isn’t it?
To understand Pfizer is to understand the inherent contradictions of the pharmaceutical industry. It is a capital-intensive undertaking, demanding vast sums for research and development. Regulatory hurdles, while necessary, further inflate costs. Competition is relentless, each company striving for dominance in narrowly defined therapeutic niches. The system is rigged, not by malice, but by its very nature. Patents offer a temporary monopoly, allowing for exorbitant profits, but this advantage inevitably erodes as generic alternatives flood the market. This ‘patent cliff,’ as it is euphemistically termed, is not a bug, but a feature.
This acquisition, representing a mere 4.2% addition to the insider’s existing portfolio, is, shall we say, a subtle flourish. It lacks the audacity of conviction, yet possesses the intrigue of a carefully considered wager. The absence of directly held shares in this transaction is, in itself, a statement—a quiet declaration of preference for the shadows of indirect ownership.
Investors remain cautious, and rightly so. Beneath the veneer of record sales lies a considerable debt, a shadow cast by the recent past. Whether this momentum can be sustained is a question best left unanswered, for the future rarely conforms to our expectations. Still, one is compelled to ask: can Carnival navigate these currents and, once again, exceed the market’s indifferent gaze?
The market, of course, is a fickle beast, easily distracted by superficial gains and losses. Berkshire has lagged behind the S&P 500 (^GSPC 0.43%) since the announcement of the succession, a predictable reaction, a collective sigh of relief amongst those who believed Buffett was Berkshire. But to equate the man with the entity is a profound misunderstanding. It is to confuse the conductor with the orchestra. The music, potentially, can continue.
The Vanguard Information Technology ETF (VGT) has demonstrated particularly robust performance, exhibiting a 120% increase over the same three-year period, outpacing the S&P 500. This raises the question of sustainability and potential downside risk, particularly as we approach 2026.
The company speaks of capital expenditures, a sum—$115 to $135 billion—that threatens to swallow lesser enterprises whole. A mere accounting detail, they claim. But I perceive within these figures a desperate striving, a feverish attempt to build a fortress against the encroaching darkness of obsolescence. Susan Li, the CFO, speaks of “Meta Superintelligence Labs.” The very phrase chills me. Is this progress, or a descent into hubris?
There are those who chase the soaring eagles, the tech darlings. Let them. I look to the workhorses, the companies that have weathered storms for generations. The ones that haven’t forgotten the weight of a loaf of bread, or the cost of a clean shirt. These “Dividend Kings,” they call them. Companies that have raised their payouts for half a century. Fifty years of keeping faith with the men and women who entrust them with a portion of their meager earnings. It’s a rare thing, in this age of fleeting loyalty.